Delving into the Latest Updates on Sirton Pharmaceuticals SpA with Synapse

概览

关联

1

项与 Sirton Pharmaceuticals SpA 相关的药物

Oligotide

靶点

HPSE

作用机制

乙酰肝素酶抑制剂 [+1]

在研机构-

原研机构

Sirton Pharmaceuticals SpA

在研适应症-

非在研适应症

糖尿病 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Sirton Pharmaceuticals SpA 相关的临床结果

登录后查看更多信息

0 项与 Sirton Pharmaceuticals SpA 相关的专利（医药）

登录后查看更多信息

2

项与 Sirton Pharmaceuticals SpA 相关的文献（医药）

Chimica Oggi

Biopolymer preparation by an integrated dynamic enzymic membrane reactor: technical and economic analysis

作者: Fedeli, G. F. ; Drioli, E. ; Diamantini, G.

Membrane technol. seems to be an interesting alternative to traditional methods of biopolymer productionTrial preparations of an antiulcer glycopeptide (Glyptide) incluses using an integrated dynamic enzymic membrane reactor (IDEMR) useful for carrying out enzymolysis simultaneously with dialysis and concentration of the substrate.With the IDEMR it is possible to remove the enzymic products and, at the same time, maintain substrate concentration; these conditions favor enzyme kinetics.The use of the IDEMR has eliminated many steps and saves production time and ≤85% of reagent quantities.Average cost reduction was 40%.

Research Communications in Alcohol and Substances of Abuse

Naltrexone to keep a drug-free condition

作者: Barchetta, Antonio ; Iacobelli, Massimo ; Barone, Saverio ; Stella, Luigi ; Rossi, Francesco ; Cassese, Francesco ; Motola, Giulia ; Mazzeo, Filomena

Opioid addiction is a chronic disease with a relapsing trend including unpredictably-long periods of remission and complete will-being, but at high risk of relapse.Selective antagonists of mu, kappa and lambda receptors of the opioid system are among the commonest therapeutic means to prevent relapses and include naltrexone.Therefore, the aim of this report was to evaluate different administration regimens for naltrexone in a 12-mo follow-up to keep a drug-free condition with respect to the different therapeutic requirements and compliance of the treated patients.Seventy-two patients (64 males and 8 females) were enrolled.Patients were divided in three groups of 24.In the 1^st group a member of the family was in charge for daily administration of the antagonist (50 mg tabs).Due to personal reasons, no psychol. support could be given to patients in this group; these patients only underwent a weekly test to rule out narcotics intake.The 2^nd group received a daily administration (50 mg tabs) by a member of their families, psychol. support and toxicol. tests twice a week.The 3^rd group received a daily administration (50 mg tabs) by a member of their families, psychol. support, toxicol. tests twice a week and antagonist administration by healthcare professionals of the Therapeutic Services every 10 days.The following results were obtained at the end of the study: in the first group, 9 patients withdrew from treatment within the first three months, 7 withdrew after 6 to 12 mo, resuming heroin use, 8 of the treated patients are currently drug-free.In the second group, 6 patients withdrew from treatment within the first three months and 6 of them after 6 to 12 mo resuming their opioid habits; 12 patients are drug-free.Finally, follow-up of the third group showed 2 and 3 patients to have withdrawn from the trial within the first three months and after 6 to 12 mo, resp., resuming their heroin habits; 19 patients of this group are currently still drug-free.The results obtained in this trial confirm that treatment with an opioid antagonist allowed us to keep a large number of patients drug-free.

100 项与 Sirton Pharmaceuticals SpA 相关的药物交易

登录后查看更多信息

100 项与 Sirton Pharmaceuticals SpA 相关的转化医学

登录后查看更多信息